Tumors of female reproductive systemTumors of female reproductive systemОпухоли женской репродуктивной системы1994-40981999-8627Publishing House ABV Press93710.17650/1994-4098-2022-18-1-87-96GYNECOLOGY. REVIEWSГИНЕКОЛОГИЯ. ОБЗОРНЫЕ СТАТЬИInterdisciplinary approach to the management of patients with uterine cancer progressionМеждисциплинарный подход к ведению пациенток при прогрессировании рака тела маткиhttps://orcid.org/0000-0001-7985-9050MorkhovK. Yu.МорховК. Ю.
Russian Federation

Oncological Department of Surgical Treatment Scientific

4 Akademika Oparina St., Moscow 117198, Russia;

Онкологическое отделение хирургических методов лечения

117198 Москва, ул. Академика Опарина, 4

k_morkhov@mail.ruhttps://orcid.org/0000-0002-7229-594XKreininaYu. M.КрейнинаЮ. М.
Russian Federation

Laboratory of Radiation Therapy and Complex Methods of Treatment of Oncological Diseases of the Research Department of Innovative Technologies for Complex Diagnosis of Diseases and Radiotherapy; Department of Oncology, Radiotherapy and Plastic Surgery

86 Profsoyuznaya St., Moscow 117485, Russia; build. 4, 2 Bolshaya Pirogovskaya St., Moscow 119435, Russia;

Лаборатория лучевой терапии и комплексных методов лечения онкологических заболеваний научно-исследовательского отдела инновационных технологий комплексной диагностики заболеваний и радиотерапии; кафедра онкологии, радиотерапии и пластической хирургии

117485 Москва, ул. Профсоюзная, 86; 119435 Москва, ул. Большая Пироговская, 2, стр. 4

https://orcid.org/0000-0001-9864-3837PokataevI. A.ПокатаевИ. А.
Russian Federation

Chemotherapeutic Treatment Service

18A Zagorodnoe Shosse

Служба химиотерапевтического лечения

117152 Москва, Загородное шоссе, 18А

https://orcid.org/0000-0002-1855-9692NechushkinaV. M.НечушкинаВ. М.
Russian Federation

Department of Oncology, Radiation Therapy and Radiation Diagnostics

18/1 Verkhnevolzhskaya Naberezhnaya, Nizhny Novgorod 603155, Russia

Кафедра онкологии, лучевой терапии и лучевой диагностики

603155 Нижний Новгород, Верхневолжская набережная, 18/1

Scientific Research Institute of Оncogynecology and Mammology, National Medical Research Center for Obstetrics, Gynecology and Perinatology named after V. I. Kulakov, Ministry of Health of RussiaИнститут онкогинекологии и маммологии ФГБУ «Научный центр акушерства, гинекологии и перинатологии им. акад. В. И. Кулакова» Минздрава РоссииRussian Scientific Center of Roentgenoradiology, Ministry of Health of RussiaФГБУ «Российский научный центр рентгенорадиологии» Минздрава РоссииFirst Moscow State Medical University named after I.M. Sechenov (Sechenov University), Ministry of Health of RussiaФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова Минздрава России (Сеченовский Университет)»City Clinical Oncology Hospital No. 1, Moscow Health DepartmentГБУЗ «Городская клиническая онкологическая больница № 1 Департамента здравоохранения г. Москвы»Privolzhsky Research Medical University, Ministry of Health of RussiaФГБОУ ВО «Приволжский исследовательский медицинский университет» Минздрава России0805202218187960805202208052022https://ojrs.abvpress.ru/ojrs/article/view/937

Endometrial cancer is the most common gynecologic malignancy in Russia. Surgery and/or chemoand radiotherapy remain standard clinical approach. This review describes multidisciplinary approach as the state of the art in the disease management. We notice the importance of molecular assessment for driving the clinic decision and newly emerging medical treatments, such as immunotherapy and antiangiogenic tyrosine kinase inhibitors and immunotherapy combinations.

Рак эндометрия является наиболее частым онкогинекологическим заболеванием в России. Хирургия и/или сочетание хирургического лечения, лучевой терапии и химиотерапии остаются стандартом его терапии. данный обзор описывает использование мультидисциплинарного подхода как современного способа ведения пациенток, страдающих раком эндометрия. При этом описаны важность молекулярной оценки в принятии решения и использование новых подходов, таких как иммунотерапия и комбинация ингибиторов контрольных точек и ингибиторов тирозинкиназ.

endometrial cancermultidisciplinary approachimmunotherapyimmune checkpoint inhibitorstyrosine kinase inhibitorsрак тела маткимультидисциплинарный подходиммунотерапияингибиторы контрольных точек иммунитетаингибиторы тирозинкиназLortet-Tieulent J., Ferlay J., Bray F. et al. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst 2018;110(4):354–361. DOI: 10.1093/jnci/djx214.Malignant tumors (n Russia in 2019 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2020. 252 p. (In Russ.).Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2020. 252 с.Creutzberg C.L., Van Putten W.L., Koper P.C. et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol2003;89(2):201–9.Creutzberg C.L., Nout R.A., Lybeert M.L. et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011;81(4):e631–8. DOI: 10.1016/j.ijrobp.2011.04.013.Yechieli R., Robbins J.R., Schultz D. et al. Vaginal recurrence more than 17 years after hysterectomy and adjuvant treatment for uterine carcinoma with successful salvage brachytherapy: A case report. Case Rep Oncol 2011;4(1):242–5. DOI:10.1159/000328076.Wylie J., Irwin C., Pintilie M. et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol Oncol 2000;77(1):66–72. DOI: 10.1006/gyno.2000.5727.Robbins J.R., Yechieli R., Laser B. et al. Is time to recurrence after hysterectomy predictive of survival in patients with early stage endometrial carcinoma? Gynecol Oncol 2012;127(1):38–42.Boruta D.M., Gehrig P.A., Fader A.N., Olawaiye A.B. Management of women with uterine papillary serous cancer: A Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009;115(1):142–53.Olawaiye A.B., Boruta D.M. Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review. Gynecol Oncol 2009;113(2):277–83.Del Carmen M.G., Boruta D.M., Schorge J.O. Recurrent endometrial cancer. Clin Obstet Gynecol 2011;54(2):266–77.Ozen A., Falchook A.D., Varia M.A. et al. Effect of race and histology on patterns of failure in women with early stage endometrial cancer treated with high dose rate brachytherapy. Gynecol Oncol 2015;138(2):429–33.Nechushkina V.M., Morkhov K.Yu., Kuznetsov V.V. Combined treatment of early-stage uterine cancer. Sibirskiy onkologichesiy zhurnal = Siberian Journal of Oncology 2013;(3):70–4. (In Russ.).Нечушкина В.М., Морхов К.Ю., Кузнецов В.В. Комбинированное лечение рака тела матки ранних стадий. Сибирский онкологический журнал 2013;(3):70–4.Mariani A., Dowdy S.C., Keeney G.L. et al. High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy. Gynecol Oncol 2004;95(1):120–6. DOI: 10.1016/j.ygyno.2004.06.042.Abusaris H., Hoogeman M., Nuyttens J.J. Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region. Technol Cancer ResTreat 2012;11(6):591–7.Alders J.G., Abeler V., Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecol Oncol 1984;17(1):85.Nechushkina V.M. Cancer of the uterine body (prognosis factors and treatment tactics). Summary of thesis … of doctor of medical sciences. Moscow, 2013. 445 p. (In Russ.).Нечушкина В.М. Рак тела матки (факторы прогноза и тактика лечения). Дис. ... д-ра мед. наук. М., 2013. 445 с.Xu Y., Burmeister C., Hanna R.K. et al. Predictors of survival after recurrence in women with early-stage endometrial carcinoma. Int J Gynecol Cancer 2016;26 (6):1137–42. DOI:10.1097/IGC.0000000000000733.Schmidt A.M., Imesch P., Fink D. et al. Pelvic exenterations for advanced and recurrent endometrial cancer: clinical outcomes of 40 patients. Int J Gynecol Cancer 2016;26(4):716–21.Lee L.J., Damato A.L., Viswanathan A.N. Clinical outcomes of high-dose-rate interstitial gynecologic brachytherapy using real-time CT guidance. Brachytherapy 2013;12(4):303–10.Hasbini A., Haie-Meder C., Morice P.et al. Outcome after salvage radiotherapy (brachytherapy ± external) in patients with a vaginal recurrence from endometrial carcinomas. Radiother Oncol 2002;65(1):23–8. DOI: 10.1016/s0167-8140(02)00212-8.Yard B.D., Adams D.J., Chie E.K. et al. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun 2016;7:11428.Cancer of the body of the uterus and uterine sarcomas. Clinical recommendations of the Ministry of Health of Russia 2021. Available at: https://oncology-association.ru/wpcontent/uploads/2021/02/rak-tela-matkii-sarkomy-matki-2021.pdf. (In Russ.).Рак тела матки и саркомы матки. Клинические рекомендации Минздрава России 2021. Доступно по: https://oncology-association.ru/wp-content/uploads/2021/02/rak-tela-matki-isarkomy-matki-2021.pdf.Lindemann K., Smogeli Е., Cvancarova Småstuen M. et al. Salvage radiation for pelvic relapse after surgically treated endometrial cancer. Cancers (Basel) 2021;13(6):1367. DOI: 10.3390/cancers13061367.Steiner A., Alban G., Cheng T. Vaginal recurrence of endometrial cancer: MRI characteristics and correlation with patient outcome after salvage radiation therapy. Abdom Radiol (NY) 2020;45(4):1122–31.Titova V.A., Stolyarova I.V., Kreinina Yu.M. Modern technologies for the complex treatment of endometrial cancer: a scientific and practical publication. Moscow, Saint Petersburg: Foliant, 2012. 168 p. (In Russ.).Титова В.А., Столярова И.В., Крейнина Ю.М. Современные технологии комплексного лечения рака эндометрия: научно-практическое издание. Москва, Санкт-Петербург: Фолиант, 2012. 168 с.Mehta S., Gupta B. Recent advances in endometrial cancer. Springer, 2020. Pp. 257–266.Jhingran A., Burke T.W., Eifel P.J. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Phys2003;56:1366–72.Blecharz P., Brandys P., Urbański K. et al. Vaginal and pelvic recurrences in stage I and II endometrial carcinoma survival and prognostic factors. Eur J Gynaecol Oncol 2011;32:403–7.Nag S., Yacoub S., Copeland L.J., Fowler J.M. Interstitial brachytherapy for salvage treatment of vaginal recurrences in previously unirradiated endometrial cancer patients. Int J Radiat Oncol Biol Phys 2002;54:1153–9. DOI: 10.1016/s0360-3016(02)03019-5.Abusaris H., Hoogeman M., Nuyttens J.J. Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region. Technol Cancer ResTreat 2012;11(6):591–7.Tran P.T., Su Z., Hara W. et al. Long-term survivors using intraoperative radiotherapy for recurrent gynecologic malignancies. Int JRadiat Oncol Biol Phys 2007;69(2):504–11.Barakat R.R., Goldman N.A., Patel D.A. et al. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999;75(1):99–102.Morris M., Alvarez R.D., Kinney W.K. et al. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 1996;60(2):288–91.Khoury-Collado F., Einstein M.H., Bochner B.H. et al. Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol 2012;124(1):42–7.Westin S.N., Rallapalli V., Fellman B. et al. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol 2014;134 (3):546–51. DOI: 10.1016/j.ygyno.2014.06.034.Ang C., Bryant A., Barton D.P. et al. Exenterative surgery for recurrent gynaecological malignancies. Cochrane Database Syst Rev 2014;4(2):CD010449.Van Wijk F.H., van der Burg M.E., Burger C.W. et al. Management of recurrent endometrioid endometrial carcinoma: an overview. Int J Gynecol Cancer 2009;19(3):314–20.Zanfagnin V., Ferrero A., Biglia N. et al. The role of surgery in recurrent endometrial cancer. Expert Rev Anticancer Ther 2016;16(7):741–50.Dowdy S.C., Mariani A., Cliby W.A. et al. Radical pelvic resection and intraoperative radiation therapy for recurrent endometrial cancer: technique and analysis of outcomes. Gynecol Oncol 2006;101(2):280–6.Deodato F., Maccia G., Grimaldi L. et al. Stereotactic radiotherapy in recurrent gynecological cancer: A case series. Oncol Rep2009;22(2):415–9.Sorolla M.A., Parisi E., Sorolla A. Determinants of sensitivity to radiotherapy in endometrial cancer. Cancers 2020;12(7): 1906. DOI: 10.3390/cancers12071906.Potters L., Steinberg M., Rose C. et al. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guidelines for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 2004;60:1026–32.Wulf J., Haedinger U., Oppitz U. et al. Stereotactic boost irradiation for targets in abdomen and pelvis. Radiother Oncol 2004;70:31–6. DOI: 10.1016/j.radonc.2003.10.013.Lee L.J., Damato A.L., Viswanathan A.N. Clinical outcomes following 3D imageguided brachytherapy forvaginal recurrence of endometrial cancer. Gynecol Oncol 2013;131(3):586–92.Piura B., Rabinovich A., Apel-Sarid L., Shaco-Levy R. Splenic metastasis from endometrial carcinoma: report of a case and review of literature. Arch Gynecol Obstet 2009;280(6):1001–6.Tangjitgamol S., Levenback C.F., Beller U., Kavanagh J.J. Role of surgical resection for lung, liver, and central nervous system metastases in patients with gynecological cancer: a literature review. Int J Gynecol Cancer 2004;14(3):399–422.Barlin J.N., Puri I., Bristow R.E. Cytoreductive surgery for advanced or recurrent endometrial cancer: a metaanalysis. Gynecol Oncol 2010;118(1):14–8.Turan T., Tasci T., Karalok A. et al. Salvage cytoreductive surgery for recurrent endometrial cancer. Int J Gynecol Cancer 2015;25(9):1623–32. DOI: 10.1097/IGC.0000000000000543.Papadia A., Bellati F., Ditto A. et al. Surgical treatment of recurrent endometrial cancer: time for a paradigm shift. Ann Surg Oncol 2015;22(13):4204–10.Awtrey C.S., Cadungog M.G., Leitao M.M. et al. Surgical resection of recurrent endometrial carcinoma. Gynecol Oncol 2006;102(3):480–8.Salama J.K., Milano M.T. Radical irradiation of extracranial oligometastases. J Clin Oncol 2014;32(26):2902–12.Kandoth C., Schultz N., Cherniack A.D. et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497:67–73. DOI: 10.1038/nature12113.National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 3.2019.Miller D., Filiaci V., Fleming G. et al. Late-breaking abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2012;125:771.Homesley H.D., Meltzer N.P., Nieves L. et al. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. Int J Clin Oncol 2008;13(1):62–5.Lincoln S., Blessing J.A., Lee R.B., Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003;88(3):277–81.Lissoni A., Zanetta G., Losa G. et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996;7(8):861–3. DOI: 10.1093/oxfordjournals.annonc. a010768.Lissoni A., Zanetta G., Losa G. et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996;7(8):861–3. DOI: 10.1093/oxfordjournals.annonc.a010768.Markman M., Fowler J. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel. Gynecol Oncol 2004;92(1):180–2.Fracasso P.M., Blessing J.A., Molpus K.L. et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;103(2):523–6.Gupta D., Owers R.L., Kim M. et al. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers. Gynecol Oncol 2009;113(3):327–30.Miller D.S., Blessing J.A., Lentz S.S., Waggoner S.E. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2002;87(3):247–51.Muggia F.M., Blessing J.A., Sorosky J., Reid G.C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002;20(9):2360–4.Rose P.G., Blessing J.A., Lewandowski G.S. et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 1996;63(1):101–4.Pawinski A., Tumolo S., Hoesel G. et al. Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group. Eur J Obstet Gynecol Reprod Biol 1999;86(2):179–83.Miller D.S., Blessing J.A., Drake R.D. et al. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology. Gynecol Oncol 2009;115(3):443–6.Tait D.L., Blessing J.A., Hoffman J.S. et al. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2011;121(1):118– 21. DOI: 10.1016/j.ygyno.2010.11.027.Sutton G.P., Blessing J.A., Homesley H.D. et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study. Cancer 1994;73(5):1453–5.Lentz S.S., Brady M.F., Major F.J. et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 1996;14:357–61.Levine D.A., Getz G., Gabriel S.B. et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67–73.Makker V., Green A.K., Wenham R.M. et al. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecol Oncol Res Pract 2017;4:19. DOI: 10.1186/s40661-0170056-7.Le D.T., Uram J.N., Wang H. et al. PD-1 blockade in tumors with mismatchrepair deficiency. N Engl J Med 2015;372:2509–20.Marabelle A., Le D.T., Ascierto P.A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol 2020;38:1–10.Mittica G., Ghisoni E., Giannone G. et al. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget 2017;8(52):90532–44.Hasegawa K., Tamura K., Katsumata N. et al. Efficacy and safety of nivolumab (Nivo) in patients (pts) with advancedor recurrent uterine cervical or corpus cancers. J Clin Oncol 2018;36(Suppl 15): 5594.Konstantinopoulos P.A., Luo W., Liu J.F. et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/ persistent endometrial cancer. J Clin Oncol 2019;37:2786–94. DOI: 10.1200/JCO.19.01021.Antill Y., Kok P.S., Stockler M. et al. Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: the phase II PHAEDRA trial (ANZGOG1601). Ann Oncol 2019;30(Suppl 9): IX192.Oaknin A., Tinker A.V., Gilbert L. et al. Clinical activity and safety of the antiprogrammed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial. JAMA Oncol 2020;6:1766–72.Clinical trials for 2018-001072-37. Available at: https://www. clinicaltrialsregister.eu/ctr-search/search?query=2018-001072-37.Clinical trials for 2018-001072-37. Available at: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-001072-37.Antill Y.C., Kok P.-S., Robledo K.P. et al. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). J Clon Oncol 2019;37(15 Suppl):5501.Arora S., Balasubramaniam S., Zhang W. et al. FDA Approval Summary: Pembrolizumab plus Lenvatinib for Endometrial Carcinoma, a Collaborative International Review under Project Orbis. Clin Cancer Res2020;26(19):5062–7. DOI:10.1158/1078-0432.CCR-19-3979.Makker V., Colombo N., Herraez A.C. et al. A multicenter, open-label, randomized, phase 3 study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer: Study 309/KEYNOTE-775.SGO Annual Meeting 2021.